Cancer Immunotherapy

T cells specific to hepatitis B viral X antigen could eradicate tumors

Published in Hepatitis Weekly, February 24th, 2003

by Sonia Nichols, senior medical writer - Scientists believe certain antigens from hepatitis B virus (HBV) could be used in adoptive immunotherapy for eradicating malignancies in the liver.

"We have reported previously several cytotoxic T lymphocyte (CTL) epitopes derived from the HBV X antigen (HBx)," said Eunyoung Chun, Mogam Biotechnology Research Institute, South Korea. "In this study, we evaluated whether HBx-specific CTLs can be effectively used in adoptive cancer immunotherapy."

Researchers elected to test two HBx epitopes known to induce CTLs in humans for their study of adoptive immunotherapy. They used those epitopes, HBx 52-60(HLSLRGLFV)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry